Summary
The provided label excerpt does not contain the specific information needed to verify the AI’s claims about allergic reactions/anaphylaxis, injection-site reactions, rash/pruritus frequency, or severe cutaneous reactions (SJS/TEN), so alignment cannot be confirmed.
Category Scores
Accurate Statements
Unsupported Statements
Azacitidine can trigger allergic reactions, including anaphylaxis in rare cases.
Not verifiable from the provided label excerpt (Section 5/6 content shown does not include allergy/anaphylaxis statements).
Symptoms of azacitidine-related anaphylaxis may include hives, itching, swelling of the face or throat, difficulty breathing, or rapid heartbeat.
Not verifiable from the provided label excerpt.
Azacitidine allergic reactions typically occur during or shortly after injection, especially with subcutaneous administration.
Not verifiable from the provided label excerpt.
Skin issues are frequent with azacitidine, affecting up to 70% of patients in clinical trials.
Not verifiable from the provided label excerpt.
Azacitidine injection-site reactions can include redness, pain, swelling, itching, bruising, or rash at the site.
Not verifiable from the provided label excerpt.
Azacitidine injection-site reactions usually resolve within days but can persist.
Not verifiable from the provided label excerpt.
Azacitidine can cause pruritus beyond the injection site.
Not verifiable from the provided label excerpt.
Azacitidine can cause urticaria (hives).
Not verifiable from the provided label excerpt.
Azacitidine can cause erythema (widespread redness).
Not verifiable from the provided label excerpt.
Azacitidine can cause rare cases of Stevens-Johnson syndrome.
Not verifiable from the provided label excerpt.
Azacitidine can cause rare cases of toxic epidermal necrolysis.
Not verifiable from the provided label excerpt.
Stevens-Johnson syndrome and toxic epidermal necrolysis are life-threatening blistering disorders requiring immediate medical attention.
Not verifiable from the provided label excerpt.
Injection-site reactions occur very commonly (>10%) with azacitidine.
Not verifiable from the provided label excerpt.
Rash or pruritus occurs commonly (1-10%) with azacitidine.
Not verifiable from the provided label excerpt.
Anaphylaxis occurs rarely (<0.1%) with azacitidine.
Not verifiable from the provided label excerpt.
Severe cutaneous reactions (e.g., Stevens-Johnson syndrome) occur very rarely with azacitidine.
Not verifiable from the provided label excerpt.
Skin disorders occurred in 31% of azacitidine patients versus 23% on conventional care in AZA-001.
Not verifiable from the provided label excerpt.
Patients on the subcutaneous form of azacitidine (Vidaza) report higher rates of local skin reactions than those on intravenous azacitidine.
Not verifiable from the provided label excerpt.
Higher risk of allergic reactions/skin reactions is associated with subcutaneous dosing.
Not verifiable from the provided label excerpt.
Higher risk of allergic reactions/skin reactions is associated with prior allergies.
Not verifiable from the provided label excerpt.
Higher risk of allergic reactions/skin reactions is associated with concurrent use of allopurinol.
Not verifiable from the provided label excerpt.
Compared with decitabine, azacitidine has more local skin reactions but similar systemic allergy rates.
Not verifiable from the provided label excerpt.
Contradictions
Important Omissions
Relevant FDA label details supporting/quantifying adverse reactions (allergic reactions/anaphylaxis, injection-site reactions, rash/pruritus, and SJS/TEN) and related incidence/risk statements cannot be assessed because the provided prompt includes only a partial Section 6 header/other-topic pointer list and does not include the actual adverse reaction content.
Importance:
High
Safety Assessment
Potential Patient Risk:
High
The response makes multiple high-safety claims (anaphylaxis and severe cutaneous reactions) and provides incidence/risk qualifiers, but none are verifiable against the supplied label excerpt.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Verifiable / Low Confidence
Primary Issue
All provided adverse-reaction and severity/incidence claims are not verifiable from the label text supplied in the prompt.
Suggested Improvement
Provide the actual FDA label text for the specific adverse reaction and warnings sections that describe allergic reactions/anaphylaxis, injection-site reactions, rash/pruritus, and SJS/TEN, and cite the exact wording/ranges used before asserting incidence or risk factors.